![]() |
JOURNAL TOOLS |
Opzioni di pubblicazione |
eTOC |
Per abbonarsi |
Sottometti un articolo |
Segnala alla tua biblioteca |
ARTICLE TOOLS |
Estratti |
Permessi |
Per citare questo articolo |
Share |


I TUOI DATI
I TUOI ORDINI
CESTINO ACQUISTI
N. prodotti: 0
Totale ordine: € 0,00
COME ORDINARE
I TUOI ABBONAMENTI
I TUOI ARTICOLI
I TUOI EBOOK
COUPON
ACCESSIBILITÀ
REVIEWS
Acta Phlebologica 2016 April;17(1):15-22
Copyright © 2016 EDIZIONI MINERVA MEDICA
lingua: Inglese
Hemo-lymphatic malformation: Klippel-Trenaunay Syndrome
Byung B. LEE, James LAREDO
Division of Vascular Surgery, Department of Surgery, George Washington University, Washington DC, USA
The majority of patients presenting with a hemolymphatic malformation (HLM) have a combined lesion consisting of a venous malformation (VM), lymphatic malformation (LM) and capillary malformation (CM), and is often known as Klippel-Trenaunay Syndrome (KTS). Occasionally the HLM has an additional vascular malformation component in addition to CM, VM and LM: arterio-venous malformation (AVM), known as Parkes-Weber Syndrome (PWS). Therefore, accurate diagnosis and management of HLM remains a challenge due to the complex combinations of extratruncular and truncular VM and LM lesions. Diagnosis should aim at the primary pathology first based on various combinations of non-to less invasive tests (e.g. Duplex ultrasonography, MRI and radionuclide lymphoscintigraphy). Selective invasive tests (e.g. arteriography, ascending or direct puncture phlebography) may be reserved for planning treatment especially when the AVM lesion is involved along with the HLM. Precise assessment of each vascular malformation component is essential in order to prioritize treatment among the different lesions and to allow appropriate treatment selection when therapy is indicated. Treatment of HLM in general aims at the underlying primary pathology first, especially for the correction of hemodynamic disturbances caused by the lesion, and then pursue to the secondary disorders. In order to improve the overall clinical management outcome, careful selection and implementation of additional treatment modalities, either surgical (e.g. marginal vein resection) or non-surgical (e.g. sclerotherapy), in addition to the basic conservative treatment regimen (e.g. compression therapy to LM), should be determined based on a consensus among a multidisciplinary team.